TrialNeuro-oncology2022

Selumetinib in children with neurofibromatosis type 1 and asymptomatic inoperable plexiform neurofibroma at risk for developing tumor-related morbidity.

Andrea M Gross et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.